Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience.

MLA

Gargiulo, Luigi, et al. “Tralokinumab Rapidly Improves Subjective Symptoms and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-Life 16-Week Experience.” Journal of Dermatological Treatment, vol. 34, no. 1, Feb. 2023, pp. 1–3. EBSCOhost, https://doi.org/10.1080/09546634.2023.2216815.

APA

Gargiulo, L., Ibba, L., Vignoli, C. A., Facheris, P., Valenti, M., Costanzo, A., & Narcisi, A. (2023). Tralokinumab rapidly improves subjective symptoms and quality of life in patients with moderate-to-severe atopic dermatitis: a real-life 16-week experience. Journal of Dermatological Treatment, 34(1), 1–3. https://doi.org/10.1080/09546634.2023.2216815

Chicago

Gargiulo, Luigi, Luciano Ibba, Carlo Alberto Vignoli, Paola Facheris, Mario Valenti, Antonio Costanzo, and Alessandra Narcisi. 2023. “Tralokinumab Rapidly Improves Subjective Symptoms and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis: A Real-Life 16-Week Experience.” Journal of Dermatological Treatment 34 (1): 1–3. doi:10.1080/09546634.2023.2216815.